Mark Forman, USA

  • Clinical (1)

    PB2.3: Interim Safety and Biomarker Data From upliFT-D Trial of PBFT02 in FTD with GRN Mutations

    Date: 20 Sep 2024Time: 09:38 - 09:42 CET